Douglas Santos Costa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Douglas Santos Costa has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Adriana Alonso Novais
Institute of Health Sciences (ICS), Federal University of Mato Grosso (UFMT), Sinop 78550-728, RS, Brazil
1 shared publication - Debora Aparecida Pires de Campos Zuccari
Laboratory of Molecular Investigation in Cancer (LMIC), Department of Molecular Biology, Faculty of Medicine of São José do Rio Preto (FAMERP), São José do Rio Preto, Brazil
1 shared publication Francine Moraes Gonçalves
Department of Molecular Biology, Cancer Molecular Research Laboratory (LIMC) FAMERP São José do Rio Preto Brazil
1 shared publication- Jucimara Colombo
Laboratório de Investigação Molecular no Câncer (LIMC), Faculdade de Medicina de São José do Rio Preto/FAMERP, Av. Brigadeiro Faria Lima 5416, São José do Rio Preto 15090-000, SP, Brazil
1 shared publication - Jéssica Rodrigues de Oliveira
Department of Veterinary Clinic and Surgery School of Agricultural and Veterinarian Sciences, Univ. Estadual Paulista, Jaboticabal São Paulo Brazil
1 shared publication - Lucas Amoroso Lopes de Carvalho
Agricultural and Livestock Microbiology Postgraduate Program, School of Agricultural and Veterinarian Sciences, São Paulo State University (UNESP), São Paulo, Brazil
1 shared publication
Latest Publications
- 21 September 2021
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 20 (1) , 164-171
Liquid biopsy can detect BRCA2 gene variants in female dogs with mammary neoplasia
Mammary tumors (MT) is one of the most prevalent malignancies in female dogs and women. Currently, molecular analyzes have shown that each tumor type presents its own genetic signature. In this context, liquid biopsy allows a comprehensive genetic characterization of the tumor, enabling early diagnosis and personalized treatment of patients. In women, deleterious mutations inherited in BRCA2 gene are associated with an increased risk of breast cancer, resistance to therapies, and worse prognosis. In female dogs, there are many divergent data on the involvement of BRCA2 gene with mammary carcinogenesis and what its pathogenic potential is. Therefore, the objective was to identify BRCA2 gene variants in 20 plasma DNA samples, from 10 newly diagnosed dogs with mammary cancer (RD), five control (CTR), and five mastectomized (MAST) patients. Eleven single nucleotide polymorphisms (SNPs) were detected, most of them in the exon 11, and two indels (deletion / insertion) in the BRCA2 gene. However, there was no statistically significant difference in the SNPs/indels detected between the groups. In addition, only one SNP (p.T1425P) and one deletion (p.L2307del) were considered deleterious using in silico computational models. Interestingly, most common variants were present in the plasma of all groups, except for the Ile2614Thr, Ile2614Val, Thr1425Pro, and p.L2307del variants. Thus, we observed that SNPs are common in the BRCA2 gene of female dogs with mammary tumors, with a similar condition identified in women with breast cancer. Liquid biopsy approach in dogs with MT is useful for genetic and therapeutic proposals.
- 21 September 2021
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 20 (1) , 164-171
Liquid biopsy can detect BRCA2 gene variants in female dogs with mammary neoplasia
Mammary tumors (MT) is one of the most prevalent malignancies in female dogs and women. Currently, molecular analyzes have shown that each tumor type presents its own genetic signature. In this context, liquid biopsy allows a comprehensive genetic characterization of the tumor, enabling early diagnosis and personalized treatment of patients. In women, deleterious mutations inherited in BRCA2 gene are associated with an increased risk of breast cancer, resistance to therapies, and worse prognosis. In female dogs, there are many divergent data on the involvement of BRCA2 gene with mammary carcinogenesis and what its pathogenic potential is. Therefore, the objective was to identify BRCA2 gene variants in 20 plasma DNA samples, from 10 newly diagnosed dogs with mammary cancer (RD), five control (CTR), and five mastectomized (MAST) patients. Eleven single nucleotide polymorphisms (SNPs) were detected, most of them in the exon 11, and two indels (deletion / insertion) in the BRCA2 gene. However, there was no statistically significant difference in the SNPs/indels detected between the groups. In addition, only one SNP (p.T1425P) and one deletion (p.L2307del) were considered deleterious using in silico computational models. Interestingly, most common variants were present in the plasma of all groups, except for the Ile2614Thr, Ile2614Val, Thr1425Pro, and p.L2307del variants. Thus, we observed that SNPs are common in the BRCA2 gene of female dogs with mammary tumors, with a similar condition identified in women with breast cancer. Liquid biopsy approach in dogs with MT is useful for genetic and therapeutic proposals.